Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0041-1345(00)02721-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlabelled: Transparent and accurate reporting in early phase dose-finding (EPDF) clinical trials is crucial for informing subsequent larger trials. The SPIRIT statement, designed for trial protocol content, does not adequately cover the distinctive features of EPDF trials. Recent findings indicate that the protocol contents in past EPDF trials frequently lacked completeness and clarity.
View Article and Find Full Text PDFUnlabelled: Early phase dose-finding (EPDF) trials are key in the development of novel therapies, with their findings directly informing subsequent clinical development phases and providing valuable insights for reverse translation. Comprehensive and transparent reporting of these studies is critical for their accurate and critical interpretation, which may improve and expedite therapeutic development. However, quality of reporting of design characteristics and results from EPDF trials is often variable and incomplete.
View Article and Find Full Text PDFLipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study.
Drugs Real World Outcomes
January 2025
Department of Cardiology, Angiology and Intensive Care Medicine, German Heart Center of the Charité, Berlin, Germany.
Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target. Recently, a 2-mL prefilled autoinjector has been developed to support the monthly 300-mg dosing regimen with a single-injection administration.
Methods And Objectives: Monthly application of 300 mg AlirRocumab (Praluent) using the 2-mL SYDNEY Device (MARS) is a non-interventional, open, prospective, multi-center cohort study conducted in Germany between 2021 and 2023 with an observational period of 12 weeks.
Enhanced photocatalytic degradation of Rhodamine B using polyaniline-coated XTiO(X = Co, Ni) nanocomposites.
Sci Rep
January 2025
Laboratory of Materials, Nanotechnologies and Environment, Center of Sciences of Materials, Faculty of Sciences, Mohammed V University in Rabat, Avenue Ibn Battouta, BP:1014, 10000, Rabat, Morocco.
In this study, novel polyaniline-coated perovskite nanocomposites (PANI@CoTiO and PANI@NiTiO) were synthesized using an in situ oxidative polymerization method and evaluated for the photocatalytic degradation of Rhodamine B (RhB) a persistent organic pollutant. The nanocomposites displayed significantly enhanced photocatalytic efficiency compared to pure perovskites. The 1%wt PANI@NiTiO achieved an impressive 94% degradation of RhB under visible light after 180 min, while 1wt.
View Article and Find Full Text PDFFeline Papillomatosis.
Viruses
January 2025
MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK.
Different types of feline papillomaviruses (PVs) are associated with a variety of skin lesions and neoplasia, such as papillomas and cell carcinomas, but the virus can also be found in healthy skin. In this review, the European Advisory Board on Cat Diseases (ABCD), a scientifically independent board of veterinary experts on feline infectious diseases from 11 European Countries, discusses the current knowledge of feline PV infections. Cats most likely become infected through lesions or abrasions of the skin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!